近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285, 1996. IF 6.250; Cited 202. Bentel JM, Buchanan G, Tilley WD. Androgen receptor gene mutations in prostate cancer. In: Naz R (ed) Frontiers in Bioscience; Prostate: Basic and Clinical Aspects.219-244, 1997. IF 2.989. Buchanan G, Tilley WD. Androgen receptor structure and function in prostate cancer. In: Li JJ, Darling JR, Li SA (eds) Hormonal Carcinogenesis III. Springer-Verlag, New York, 333-341, 2000. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF, Coetzee GA. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 60:5946-5949, 2000. IF 7.672; Cited 89 Buchanan G, Yang M, Nahm SJ, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM, Tilley WD. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 15:46-56, 2001. IF 5.337; Cited 52. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD, Greenberg NM Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 276: 11204-11213, 2001. IF 5.581; Cited 63. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7: 1273-1281, 2001. IF 6.250; Cited 73. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev. 20:207-223, 2002. IF 6.766; Cited 59. James AJ, Agoulnik IU, Harris JM, Buchanan G, Tilley WD, Marcelli M, Lamb DJ, Weigel NL. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol. 16:2692-705, 2002. IF 5.337; Cited 9. Tilley WD, Buchanan G, and Coetzee GA. Androgen receptor signaling in prostate cancer. In: Henderson, BE, Ponder B, Ross RK (eds) Hormones, Genes and Cancer Oxford University Press, New York, 288-315, 2003. Cited 5. Buchanan G, Craft PS, Yang M, Cheong A, Prescott J, Jia L, Coetzee GA, Tilley WD. PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate. 60:352-66, 2004. IF 3.674; Cited 5. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration resistant prostate cancer. Endocr Relat Cancer. 11:459-76, 2004. IF 5.193; Cited 42. Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA, Tilley WD. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet. 13:1677-92, 2004. IF 7.806; Cited 39. Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, Marshall VR, Horsfall DJ, Tilley WD. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate. 63:19-28, 2005. IF 3.674; Cited 15. Shen HC, Buchanan G, Butler LM, Prescott J, Henderson M, Tilley WD, Coetzee GA. GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. Biol Chem, 386:69-74, 2005. IF 2.840; Cited 5. Han G, Buchanan G, Harris JM, Ittmann M, Yu X, DeMayo FJ, Tilley WD, Greenberg NM. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA. 102:1151-1156, 2005. IF 9.598; Cited 55. Makridakis NM, Buchanan G, Tilley WD, Reichardt JK. Androgen metabolic genes in prostate cancer predisposition and progression. Frontiers in Bioscience. 10:2892-2903, 2005. Beekman KW, Buchanan G, Tilley WD, Scher HI. Anti-Androgen Withdrawal Syndromes: Pathophysiology and Clinical Implications. In: Partin AW (Ed) Prostate Cancer: Principles and Practice. Lippincott, Philadelphia. Beekman KW, Buchanan G, Tilley WD, Scher HI. Beyond first line hormones: options for castration-resistant disease. In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM (Eds). Comprehensive Textbook of Genitourinary Oncology (Third Edition). Wiley and Williams, Lippincott, Philadelphia, 330-340, 2005. Buchanan G, Birrell SN, Ramsay K, Yang M, Harris JM, Simila HA, Peters AA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM, Tilley WD. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res. 65:8487-8496, 2005. IF 7.672; Cited 15.